| P50 | author | Kinga Majchrzak-Kuligowska | Q64160867 |
| P2093 | author name string | Michelle Hase Nelson | |
| | Joanna Katarzyna Bujak | |
| | Rafał Pingwara | |
| P2860 | cites work | CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma | Q75225386 |
| | TREATMENT OF PRIMARY FIBROSARCOMA IN THE RAT WITH IMMUNE LYMPHOCYTES | Q76846083 |
| | Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity | Q77929305 |
| | The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase | Q81000005 |
| | T-lymphocytic infiltrate in canine mammary tumours: clinic and prognostic implications | Q82162186 |
| | Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience | Q83222464 |
| | Density of tumor-associated macrophages (TAMs) and expression of their growth factor receptor MCSF-R and CD14 in canine mammary adenocarcinomas of various grade of malignancy and metastasis | Q83996082 |
| | Flow cytometric analysis of peripheral blood and tumor-infiltrating regulatory T cells in dogs with oral malignant melanoma | Q84189316 |
| | Decrease of E-cadherin expression in canine cutaneous histiocytoma appears to be related to its spontaneous regression | Q84216902 |
| | Significance of tumor-infiltrating immune cells in spontaneous canine mammary gland tumor: 140 cases | Q84972473 |
| | Immunosuppression in Dogs During Mammary Cancer Development | Q89282901 |
| | The Hallmarks of Cancer | Q221226 |
| | Lymphocyte infiltration, expression of interleukin (IL) -1, IL-6 and expression of mutated breast cancer susceptibility gene-1 correlate with malignancy of canine mammary tumours. | Q54451751 |
| | Reconstitution of MHC class I specificity by transfer of the T cell receptor and Lyt-2 genes | Q57275641 |
| | The dog as a cancer model | Q57634513 |
| | Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells | Q60634986 |
| | High Number of Intraepithelial CD8+Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer | Q61626227 |
| | Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report | Q68100559 |
| | Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor | Q72059554 |
| | Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro | Q72405827 |
| | Bulk cultures of canine peripheral blood lymphocytes with solid phase anti-CD3 antibody and recombinant interleukin-2 for use in immunotherapy | Q73224192 |
| | Tumor cell-induced deactivation of human monocytes | Q73910628 |
| | Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma | Q74535384 |
| | TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu | Q21131200 |
| | Focus on adoptive T cell transfer trials in melanoma | Q21328679 |
| | Genome sequence, comparative analysis and haplotype structure of the domestic dog | Q22122465 |
| | Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells | Q40397520 |
| | Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes | Q40401451 |
| | Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer | Q41069577 |
| | Implications for immunosurveillance of altered HLA class I phenotypes in human tumours | Q41370602 |
| | Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma | Q41850484 |
| | A role for T-lymphocytes in human breast cancer and in canine mammary tumors | Q41966647 |
| | Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers | Q42367177 |
| | Generation of gene-target dogs using CRISPR/Cas9 system | Q43472142 |
| | Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. | Q44585173 |
| | Variation in age at death of dogs of different sexes and breeds | Q44698729 |
| | Transfer of specificity by murine alpha and beta T-cell receptor genes | Q44774041 |
| | Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression | Q45201798 |
| | Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy | Q45858516 |
| | Leukaemia success heralds wave of gene-editing therapies | Q45880622 |
| | Infiltration of CD3⁺ and CD68⁺ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors | Q46069657 |
| | Phenotypic analysis and effects of sequential administration of activated canine lymphocytes on healthy beagles | Q46155322 |
| | Comparative Aspects of Canine Melanoma | Q46594568 |
| | Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors | Q47299684 |
| | Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells | Q47913842 |
| | Allelic inclusion of T cell receptor alpha genes poses an autoimmune hazard due to low-level expression of autospecific receptors | Q47992225 |
| | Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes | Q48561611 |
| | Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells | Q24540135 |
| | Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma | Q24548019 |
| | Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens | Q24644442 |
| | Adoptive cell transfer: a clinical path to effective cancer immunotherapy | Q24644774 |
| | Cancer regression in patients after transfer of genetically engineered lymphocytes | Q24654976 |
| | Cancer immunoediting from immune surveillance to immune escape | Q24655415 |
| | Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes | Q24676216 |
| | Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy | Q26773309 |
| | A One Health overview, facilitating advances in comparative medicine and translational research | Q26970801 |
| | Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis | Q27024810 |
| | Immunity, Inflammation, and Cancer | Q27861048 |
| | Therapeutic genome editing: prospects and challenges | Q28087380 |
| | Development and applications of CRISPR-Cas9 for genome engineering | Q28241526 |
| | In vivo genome editing restores haemostasis in a mouse model of haemophilia | Q28241725 |
| | Genome editing with engineered zinc finger nucleases | Q28290795 |
| | Comparative oncology: what dogs and other species can teach us about humans with cancer | Q28607304 |
| | ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering | Q29615505 |
| | Chimeric antigen receptor-modified T cells for acute lymphoid leukemia | Q29620130 |
| | Canine cancer immunotherapy studies: linking mouse and human | Q30239893 |
| | Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates | Q33595267 |
| | Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer | Q33689478 |
| | MDSCs mediate angiogenesis and predispose canine mammary tumor cells for metastasis via IL-28/IL-28RA (IFN-λ) signaling. | Q33975551 |
| | Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. | Q34040385 |
| | Adoptive cell transfer as personalized immunotherapy for human cancer | Q34043643 |
| | Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients | Q34111120 |
| | Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor | Q34122292 |
| | Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma | Q34300883 |
| | Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. | Q34314036 |
| | Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity | Q34326400 |
| | TALEN and CRISPR/Cas Genome Editing Systems: Tools of Discovery. | Q34394269 |
| | Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells | Q34415738 |
| | The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo | Q34459390 |
| | NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. | Q34485950 |
| | Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity | Q34592273 |
| | New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape | Q35300077 |
| | Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma | Q35604043 |
| | Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy | Q35752854 |
| | A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. | Q36057568 |
| | Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy | Q36205561 |
| | A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer | Q36299662 |
| | Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy | Q36328394 |
| | TALENs: a widely applicable technology for targeted genome editing | Q36540717 |
| | CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection | Q36637922 |
| | Cellular and molecular mechanisms of tumor-induced T-cell tolerance | Q36737702 |
| | Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure | Q36781992 |
| | At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy | Q36935749 |
| | Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer | Q36977523 |
| | Translation of new cancer treatments from pet dogs to humans | Q37059654 |
| | Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. | Q37095348 |
| | Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. | Q37181372 |
| | Adoptive immunotherapy of cancer using CD4(+) T cells | Q37275304 |
| | Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells | Q37389364 |
| | Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis | Q37536862 |
| | A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy | Q37555940 |
| | Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells. | Q37602251 |
| | Building better chimeric antigen receptors for adoptive T cell therapy | Q37707458 |
| | The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer | Q37716589 |
| | Molecular immunology lessons from therapeutic T-cell receptor gene transfer | Q37766303 |
| | CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. | Q38011892 |
| | Tumor-associated macrophages as major players in the tumor microenvironment | Q38240110 |
| | Potential pitfalls of CRISPR/Cas9-mediated genome editing | Q38624926 |
| | Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma. | Q38758789 |
| | Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells | Q39133062 |
| | Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling | Q39452134 |
| | Change in peripheral blood lymphocyte count in dogs following adoptive immunotherapy using lymphokine-activated T killer cells combined with palliative tumor resection | Q39582691 |
| | Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. | Q39630204 |
| | Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes | Q39733329 |
| | Phenotypical characterization of lymphocytes infiltrating regressing papillomas. | Q39877177 |
| | Designer T cells by T cell receptor replacement. | Q40218076 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | veterinary oncology | Q7923724 |
| | neoplasm | Q1216998 |
| | dog disease | Q53542448 |
| | animal disease model | Q64732998 |
| P304 | page(s) | 60 | |
| P577 | publication date | 2018-10-11 | |
| P1433 | published in | Acta Veterinaria Scandinavica | Q15763576 |
| P1476 | title | Adoptive cell transfer: new perspective treatment in veterinary oncology | |
| P478 | volume | 60 | |